Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
NeuroPace (NPCE)
NASDAQ:NPCE
NeuroPace (NPCE) Stock Price & Analysis
105 Followers
NPCE Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.00 - $18.15
Previous Close$8.07
Volume39.40K
Average Volume (3M)124.03K
Market Cap
$232.16M
Enterprise Value$246.30M
Total Cash (Recent Filing)$58.95M
Total Debt (Recent Filing)$73.08M
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 13, 2024EPS Estimate
-$0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.18
Shares Outstanding28,768,128
10 Day Avg. Volume78,243
30 Day Avg. Volume124,031
Standard Deviation0.46
R-Squared0.04
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)9.30
Price to Sales (P/S)2.94
Price to Cash Flow (P/CF)-14.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.57
Enterprise Value/Gross Profit5.12
Enterprise Value/Ebitda-14.22
Forecast
1Y Price Target
$17.00Price Target Upside109.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
NeuroPace News
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Product EffectivenessSignificant clinical data supports RNS over VNS or DBS for epilepsy treatment.
Financial StabilityCash reserves remain strong and debt maturity has been extended, reflecting a stable financial position.
Market ExpansionExpansion of RNS into the community could significantly increase the Total Addressable Market, offering a substantial growth opportunity for NPCE.
Bears Say
Commercial Strategy ClaritySome concerns exist due to the lack of specific details provided on commercial dynamics, which could lead to pushback from stakeholders.
Earnings ReportFollowing first quarter results, shares sold off nearly 40%.
Financial HealthQ4 cash burn increased to $3.4M from $2.2M in Q3, showing higher expenditure.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NPCE FAQ
What was NeuroPace’s price range in the past 12 months?
NeuroPace lowest stock price was $4.00 and its highest was $18.15 in the past 12 months.
What is NeuroPace’s market cap?
Currently, no data Available
When is NeuroPace’s upcoming earnings report date?
NeuroPace’s upcoming earnings report date is Aug 13, 2024 which is in 18 days.
How were NeuroPace’s earnings last quarter?
NeuroPace released its earnings results on May 08, 2024. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.321 by $0.001.
Is NeuroPace overvalued?
According to Wall Street analysts NeuroPace’s price is currently Undervalued.
Does NeuroPace pay dividends?
NeuroPace does not currently pay dividends.
What is NeuroPace’s EPS estimate?
NeuroPace’s EPS estimate is -$0.3.
How many shares outstanding does NeuroPace have?
NeuroPace has 28,768,127 shares outstanding.
What happened to NeuroPace’s price movement after its last earnings report?
NeuroPace reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.321. Following the earnings report the stock price went down -36.746%.
Which hedge fund is a major shareholder of NeuroPace?
Among the largest hedge funds holding NeuroPace’s share is EntryPoint Capital, LLC. It holds NeuroPace’s shares valued at 22K.
---
NeuroPace Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$17.00 (109.36% Upside)
$17.00 (109.36% Upside)
Blogger Sentiment
Bullish
NPCE Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $434.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
94.45%
12-Months-Change
Fundamentals
Return on Equity
-150.63%
Trailing 12-Months
Asset Growth
-6.98%
Trailing 12-Months
Company Description
NeuroPace
NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.
---
NPCE Company Deck
---
NPCE Earnings Call
Q1 2024
0:00 / 0:00
---
NPCE Stock 12 Month Forecast
Average Price Target
$17.00
▲(109.36% Upside)
Technical Analysis
Best Analysts Covering NPCE
1 Year
1 Year Success Rate
8/13 ratings generated profit
1 Year Average Return
+67.32%
reiterated a buy rating 2 months ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 61.54% of your transactions generating a profit, with an average return of +67.32% per trade.
---